Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A. P. MacGowan is active.

Publication


Featured researches published by A. P. MacGowan.


European Journal of Clinical Microbiology & Infectious Diseases | 1990

In vitro antimicrobial susceptibility of Listeria monocytogenes isolated in the UK and other Listeria species.

A. P. MacGowan; H. A. Holt; M.J. Bywater; D. S. Reeves

The MICs and MBCs of 21 antimicrobial agents were determined for 103 strains ofListeria monocytogenes isolated in the UK and 27 strains of otherListeria species. Ampicillin, penicillin, azlocillin, imipenem, gentamicin, netilmicin, amikacin, erythromycin, rifampicin, trimethoprim, clindamycin and vancomycin had good activity, while cephalothin, chloramphenicol, ciprofloxacin and ofloxacin were less active, and cefuroxime, enoxacin, norfloxacin and fosfomycin were the least active. Tetracycline had good activity against many strains, but the MIC was high for some. Unlike the otherListeria species tested,Listeria ivanovii was susceptible to fosfomycin. Inoculum size and media employed were shown to affect the MBC, tryptose phosphate broth yielding higher MBCs than Mueller-Hinton or Isosensitest broths.


The Lancet | 1997

Treatment of listeria meningitis

Em Jones; Robin A Howe; A. P. MacGowan

SIR—Jennifer Calder (Aug 2, p 307–08) highlights the importance of including Listeria monocytogenes infection in the differential diagnosis of adults with meningitis, but her interpretation of the treatment options requires clarification. Ampicillin with or without an aminoglycoside remains the best treatment for meningitis caused by L monocytogenes. Despite early reports of penicillin resistance in L monocytogenes, more recent work and much clinical experience have shown that ampicillin and penicillin, given in daily doses of more than 6 g, are probably equally effective against L monocytogenes. Cherubin and colleagues found that 32% of L monocytogenes isolates from patients with listeria meningitis were resistant to ampicillin. However, this information was derived from a retrospective review of cases and not from a formal study of in-vitro sensitivities, and methodological variations may explain this apparently high resistance rate. microscopy. The most encouraging advance in diagnostic techniques is the stool ELISA which can detect the E histolytica/E dispar antigen and the specific E histolytica antigen. Haque and co-workers study of 2000 children in Bangladash showed that the detection of E histolytica antigen in stool was highly specific compared with isoenzyme analysis and did not crossreact with other pathogens. Hitherto, epidemiological surveys on the prevalence of amoebiasis could scarcely differentiate between E histolytica and E dispar in between excreted cysts and trophozoites. Hague and colleagues estimated that at least 90% of the excreted protozoa were non-pathogenic. Use of a stool ELISA for the detection of the E histolytica antigen can improve the accuracy of diagnosis.


Infection | 1990

An open study of the efficacy and safety of single dose fosfomycin trometamol in treatment of hospitalised patients with urinary tract infection (pilot study)

A. P. MacGowan; R.A. Bailey; W. Egner; D. M. Picken; D. S. Reeves

SummarySingle dose fosfomycin trometamol (3 g) was used to treat 20 hospitalised patients with UTI. Tolerance was good or excellent in 19/20 patients; a satisfactory bacteriological outcome was recorded in 11/17 of patients with sensitive organisms and a satisfactory clinical outcome was noted in 12/16 symptomatic individuals.ZusammenfassungZwanzig stationäre Patienten, die an Harnwegsinfektionen litten, wurden mit einer Einmaldosis von 3 g Fosfomycin Trometamol behandelt. 19 der 20 Patienten vertrugen die Medikation ausgezeichnet; das bakteriologische Ergebnis war in 11 von 17 Fällen mit empfindlichem Erregerisolat zufriedenstellend. 12 der 16 symptomatischen Patienten wiesen ein befriedigendes klinisches Ergebnis auf.


Journal of Antimicrobial Chemotherapy | 2013

Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001–07—authors' response

Rosy Reynolds; Russell Hope; Marina Warner; A. P. MacGowan; David M. Livermore; Matthew J. Ellington

Sir, Lawes et al. favour an alternative interpretation of our results, suggesting that upward creep in vancomycin MIC occurred but was undetectable in the stored samples because its mechanism was unstable. The group’s two published studies, cited to support this view, are difficult to assess because they lack control data and estimates of variability. Among four susceptibility testing methods used by Edwards et al., only Etest at the time of isolation gave any indication of creep, the mode MIC for 15 isolates collected in 2010 being half a doubling dilution higher than for the isolates from each of the preceding 3 years. Ludwig et al., also using Etest, reported that the MICs of vancomycin for Staphylococcus aureus declined during storage at 2708C, and more rapidly for isolates with higher (.1 mg/L) MICs. Edwards et al. acknowledge that their results are unusual insofar as they found higher MICs (for stored isolates) by broth microdilution than Etest, conflicting with the results of other published studies; broth microdilution MICs for stored isolates were not significantly different from the initial results using Etest. They did not use agar dilution, complicating any comparison with our work. Edwards et al. suggest that changes in the MICs of vancomycin took place within the first 6 months of storage; Lawes et al. state that declines in MIC ‘continued even at 9 months’, but Ludwig et al. describe this later fall only for daptomycin, with declines in MICs of vancomycin occurring earlier (within 3 months), despite the fact that these two agents have closely related MICs for staphylococci. The biggest problem is the lack of information about the variability of MIC measurements in the two studies. ‘Careful quality control checks to standardize methods and minimize interobserver error’ are noted by Lawes et al., but are supported only by evidence of good agreement in reading the Etest zones, with no evidence for the reproducibility of the actual MIC measurements; nor do the authors give MICs for control strains. Edwards et al. acknowledge that they ‘did not seek to prove the reproducibility of MIC results for each of the testing methods, which may limit conclusions about intermethod differences’. This caveat equally limits conclusions about differences between MICs measured at different times, since the ‘acceptable’ range for control MICs—spanning at least two doubling dilutions in both the CLSI and EUCAST guidelines—greatly exceeds the MIC creep claimed by any group. Unless MICs are reproducible within a very much narrower tolerance, apparent variation over time may be experimental, not biological, as illustrated by our own experience. Our original MICs were obtained by testing batches of isolates retrieved from frozen storage—mostly at least 6 months after collection and therefore after any postulated unstable resistance would have been lost. The original results nonetheless gave the impression of MICs rising significantly over time, but this was refuted when the isolates from different years were retested together. Lawes et al. are mistaken in believing that, for the appearance of MIC creep in our original results to be explained by experimental factors confounded with the time of collection, there would have to be systematic error over time (not just a random error within and between laboratories) and that this would require a consistent change in experimental practice across 19 laboratories over 7 years. Our study quite simply did not use results measured by the 19 contributing laboratories: both the original and re-test MICs were measured at one central laboratory. Furthermore, it is easy to show by simulation that if even a small proportion of the total experimental variation is (randomly) associated with the year of collection, spuriously significant trends over time become common; the error does not have to be systematic over time. A further difficulty with the hypothesis that upward creep in MIC has occurred, but is undetectable in stored samples, is its weakness in explaining our observations on teicoplanin. Teicoplanin and vancomycin share a mechanism of action, and their MICs are positively and strongly correlated. In our original results, the MICs of vancomycin appeared to rise whereas those of teicoplanin appeared to fall. It would be a most unusual resistance mechanism that had opposite effects on the MICs of two related antimicrobials. Such a discrepancy is, however, entirely consistent with experimental variation between years. We would welcome greater research attention on, and understanding of, the issues of precision, accuracy, repeatability and reproducibility in MIC testing by various methods. Meanwhile, in this case, we remain unconvinced by our colleagues’ critique of our findings.


Journal of Antimicrobial Chemotherapy | 2001

A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital

Mandy Wootton; Ra Howe; R. Hillman; Timothy R. Walsh; Peter M. Bennett; A. P. MacGowan


Journal of Antimicrobial Chemotherapy | 2000

Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome

I. Harding; A. P. MacGowan; L. O. White; E. S. R. Darley; V. Reed


Journal of Antimicrobial Chemotherapy | 2001

A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum

C. M. Tobin; Julie Sunderland; L. O. White; A. P. MacGowan


Journal of Antimicrobial Chemotherapy | 1998

Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints.

P E Gosden; J. M. Andrews; Karen E. Bowker; H A Holt; A. P. MacGowan; D. S. Reeves; J Sunderland; R Wise


Journal of Antimicrobial Chemotherapy | 1997

Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria.

A. P. MacGowan; K. E. Bowker; H. A. Holt; Mandy Wootton; D. S. Reeves


Journal of Antimicrobial Chemotherapy | 1997

Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea.

A. P. MacGowan; R Feeney; I. M. Brown; S. Y. McCulloch; D. S. Reeves; A. M. Lovering

Collaboration


Dive into the A. P. MacGowan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge